Media Centre

Featured Media Release
 

26 Mar 2014 - GSK RECALLS NICOTINE LOZENGES FROM WAREHOUSES AND DISTRIBUTORS

GSK is in the process of voluntarily recalling from warehouses and distributors a number of batches of nicotine lozenges sold globally, after we detected manufacturing issues affecting some batches. In some cases, the lozenges were larger or smaller than GSK’s manufacturing standards.

 
 

Media Releases


Kimbra launches campaign to urge effective asthma management

Asthma Awareness Week – Popular recording artist and asthma sufferer Kimbra is joining forces with asthma experts and peak respiratory health groups today to launch the Asthma: Take Control campaign. The national campaign is urging people affected...

02/09/2014

 

Medicines Research Unit to Close

GSK today announced it will be closing the Medicines Research Unit at the Prince of Wales Hospital in Sydney.

28/08/2014

 

GSK Open Innovation brings opportunities to Australian & NZ innovators

An innovation program that helps develop ground-breaking health sector ideas around the world is calling upon Australian and New Zeland innovators to submit their ideas to the GSK Open Innovation website.

07/08/2014

 

GSK Response to Publication of Paracetamol in Low Back Pain Study (PACE)

Panadol is approved by the TGA for the effective relief of backache.

24/07/2014

 

New medicine for lupus now available in Australia

GSK is pleased to announce that BENLYSTA® (belimumab) is now available in Australia for use as an add-on therapy in adult patients with active, autoantibody-positive systemic lupus erythematosus (SLE) with a high degree of disease activity despite...

23/07/2014

 

Incruse® Ellipta® (umeclidinium) approved in Australia for Chronic Obstructive Pulmonary Disease

GlaxoSmithKline has announced today that the Therapeutic Goods Administration (TGA) has approved Incruse® Ellipta® (umeclidinium), a maintenance treatment to relieve symptoms in Australian adult patients with chronic obstructive pulmonary disease...

15/07/2014

 

Anoro® Ellipta® approved in Australia for Chronic Obstructive Pulmonary Disease

GlaxoSmithKline (GSK) and Theravance, Inc. (NASDAQ: THRX) have proudly announced that the Therapeutic Goods Administration (TGA) has approved Anoro® Ellipta® (umeclidinium/vilanterol) as a maintenance bronchodilator treatment to relieve symptoms in...

09/07/2014

 

GSK RECOGNISES TOP POPPY GROWERS

Leaders in Australian poppy production, GSK awarded its top poppy producers at an award dinner

30/06/2014

 

$80,000 to local communities to boost immunisation

GSK’s 2014 Immunisation Grants for local communities were launched today at the Public Health Association of Australia’s 14th annual immunisation conference. The grants aim to help improve access, coverage and timely delivery of vaccination services.

17/06/2014

 

GSK Response to CHOICE Media Release

GSK would like to respond to some of the allegations made in the CHOICE media release – Pain Pills Hurting The Hip Pocket.

12/06/2014

1 2 3 4 5 6 7 8 9 10 11 >